160 related articles for article (PubMed ID: 38376511)
1. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.
Storck W; de Laportalière TT; Yrondi A; Javelot H; Berna F; Montastruc F
Psychopharmacology (Berl); 2024 Jun; 241(6):1205-1212. PubMed ID: 38376511
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database.
de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL
Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063
[TBL] [Abstract][Full Text] [Related]
3. An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.
Nguyen TT; Pariente A; Montastruc JL; Lapeyre-Mestre M; Rousseau V; Rascol O; Bégaud B; Montastruc F
Br J Clin Pharmacol; 2017 Mar; 83(3):612-622. PubMed ID: 27687785
[TBL] [Abstract][Full Text] [Related]
4. Reporting Patterns of Sialorrhea Comparing Users of Clozapine to Users of Other Antipsychotics: A Disproportionality Analysis Using VigiBase.
Man WH; Wilting I; Souverein P; Meyboom R; Egberts T; Heerdink ER
J Clin Psychopharmacol; 2020; 40(3):283-286. PubMed ID: 32332463
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
Bordet C; Garcia P; Salvo F; Touafchia A; Galinier M; Sommet A; Montastruc F
Psychopharmacology (Berl); 2023 Jan; 240(1):199-202. PubMed ID: 36515735
[TBL] [Abstract][Full Text] [Related]
6. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
[TBL] [Abstract][Full Text] [Related]
7. A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.
Yan Y; Wang L; Yuan Y; Xu J; Chen Y; Wu B
Expert Opin Drug Saf; 2024 Jun; 23(6):771-776. PubMed ID: 37615268
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotics and obsessive-compulsive disorder/obsessive-compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system.
Burk BG; DiGiacomo T; Polancich S; Pruett BS; Sivaraman S; Birur B
Acta Psychiatr Scand; 2023 Jul; 148(1):32-46. PubMed ID: 37194481
[TBL] [Abstract][Full Text] [Related]
9. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database.
Gastaldon C; Schoretsanitis G; Arzenton E; Raschi E; Papola D; Ostuzzi G; Moretti U; Seifritz E; Kane JM; Trifirò G; Barbui C
Drug Saf; 2022 Dec; 45(12):1539-1549. PubMed ID: 36400895
[TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database.
de Filippis R; Kane JM; Arzenton E; Moretti U; Raschi E; Trifirò G; Barbui C; De Fazio P; Gastaldon C; Schoretsanitis G
Drug Saf; 2024 May; ():. PubMed ID: 38722481
[TBL] [Abstract][Full Text] [Related]
11. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case.
Meyer-Massetti C; Vaerini S; Rätz Bravo AE; Meier CR; Guglielmo BJ
Int J Clin Pharm; 2011 Oct; 33(5):806-14. PubMed ID: 21809143
[TBL] [Abstract][Full Text] [Related]
14. Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Cepaityte D; Siafis S; Egberts T; Leucht S; Kouvelas D; Papazisis G
Schizophr Bull; 2021 Apr; 47(3):672-681. PubMed ID: 33289848
[TBL] [Abstract][Full Text] [Related]
15. Hyponatraemia as an adverse drug reaction of antipsychotic drugs: a case-control study in VigiBase.
Mannesse CK; van Puijenbroek EP; Jansen PA; van Marum RJ; Souverein PC; Egberts TC
Drug Saf; 2010 Jul; 33(7):569-78. PubMed ID: 20553058
[TBL] [Abstract][Full Text] [Related]
16. Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase
Kaguelidou F; Valtuille Z; Durrieu G; Delorme R; Peyre H; Treluyer JM; Montastruc F; Chouchana L
Drug Saf; 2023 Jan; 46(1):77-85. PubMed ID: 36459374
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
18. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase.
Montastruc F; Palmaro A; Bagheri H; Schmitt L; Montastruc JL; Lapeyre-Mestre M
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1556-65. PubMed ID: 26256010
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced tics: An observational postmarketing study.
Touafchia D; Montastruc F; Lapeyre-Mestre M; Rousseau V; Chebane L; Revet A
Hum Psychopharmacol; 2020 Jul; 35(4):e2734. PubMed ID: 32352603
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
